Government of Canada secures avian influenza vaccine to protect high-risk individuals

The Public Health Agency of Canada (PHAC) has announced the purchase of 500,000 doses of GSK’s human vaccine against avian influenza as a part of its ongoing efforts to safeguard public health.

This proactive measure aims to protect individuals at higher risk of exposure to avian influenza, particularly those in close contact with infected animals.

Although the current risk to the general public remains low, those with increased exposure to infected animals are advised to take necessary precautions. Canada reported its first domestically acquired human case of avian influenza A (H5N1) on November 9, 2024. To date, there has been no evidence of sustained human-to-human transmission of the virus globally, but avian influenza can cause severe illness in humans.

Mark Holland, Minister of Health, says as the government confronts the ongoing global health risks posed by avian influenza, their priority remains protecting the health of people in Canada.

“The proactive steps we are taking, including securing vaccine doses, reflect our commitment to being prepared for any potential public health threats,” explains Minister Holland.

The vaccine distribution will follow and equitable and risk-based approach, with 60 per cent of doses allocated to provinces and territories and 40 per cent retained in a federal stockpile for national preparedness.